natgillin/translations-raw huggingface dataset:
System according to any one of claims 1-31, wherein the extractable product is compacted into a tablet (58, 60, 62, 64, 66). 
Kapsula prema bilo kojem od prethodnih zahtjeva, naznačena time, da je zbijeni sastojak za piće dopremljen u obliku tablete.
The method of any one of claims 8 to 10 wherein the cavities of the surface are each suitable for hosting a single granule of predetermined dimensions. 
Metoda iz bilo kojeg od patentnih zahtjeva 8 do 10 pri čemu je svaka od šupljina na površini pogodna za pojedinu granulu predodređenih dimenzija.
A counter as claimed in claim 28 wherein the rotating of said first ring member is performed in response to the dispenser being actuated. 
Brojač kao što je zahtijevano u patentnom zahtjevu 25 gdje je rotacija navedenog prvog prstenastog člana (201) izvedena kao odgovor na dispenzer koji je aktiviran.
In certain preferred embodiments, the smooth muscle which is relaxed according to this method is at least one selected from the group consisting of a gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, corpus cavemosum, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle. 
Upotreba temeljem zahtjeva 20, naznačena time da je glatki mišić za relaksaciju prema ovom postupku barem jedan izabran iz skupine u kojoj su gastrointestinalni glatki mišić, analni sfinkter, sfinkter mišića jednjaka, corpus cavernosum, Oddijev sfinkter, arterijski glatki mišić, srčani glatki mišić, plućni glatki mišić, glatki mišić bubrega, glatki mišić maternice, vaginalni glatki mišić, cervikalni glatki mišić, glatki mišić posteljice, i očni glatki mišić.
Immunostimulatory composition according to claim 1, wherein the at least one free mRNA and/or the at least one mRNA of the adjuvant component are GC-stabilized. 
Imunostimulacijski pripravak prema bilo kojem zahtjevu od 1 do 7, naznačen time da su barem jedna slobodna mRNK i/ili barem jedna (m)RNK iz komponente adjuvanta GC-stabilizirane.
a contiguous sequence of the human λ light chain locus that spans from Vλ3-12 to Vλ3-1; 
(a) susjedne sekvence lokusa humanog lakog 2 lanca koja se proteže od VA3-12 do V23-1;
A cellulose-based fibre which contains at least 90 % wt of crystallised cellulose. 
Vlakno bazirano na celulozi naznačeno time da sadrži barem 90 % tež. kristalizirane celuloze.
The polypeptide of clause 36, wherein the polypeptide comprises a polypeptide having the amino acid sequence of SEQ ID NO:24 and a polypeptide having the amino acid sequence of SEQ ID NO:32. 
Protutijelo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da obuhvaća polipeptid koji ima aminokiselinsku sekvencu od SEQ ID NO:22 i polipeptid koji ima aminokiselinsku sekvencu od SEQ ID NO:26 ili SEQ ID NO:30.
The method of claim 1, wherein said effective amount is from 1 to 25 mg of said lipophilic extract of Zingiber officinale and from 1 to 10 mg of said lipophilic extract of Echinacea angustifolia per dose. 
Upotreba: a) lipofilnog ekstrakta Zingiber officinale, te b) lipofilnog ekstrakta Echinacea angustifolia, koji se dobivaju ekstrakcijom s ugljičnim dioksidom pri superkritičnim uvjetima, naznačena time da je za preparaciju pripravaka za prevenciju 1 liječenje gastroezofagealne refluksne bolesti.
The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R1 is H; or wherein R2 is H; or wherein R3 is H; or wherein R4 is H; or wherein R5 is H; or wherein R7 is H; or wherein R8 is H; or wherein R9 is H. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, pri čemu R1 je H; ili pri čemu R2 je H; ili pri čemu R5 je H; ili pri čemu R7 je H; ili pri čemu R8 je H; ili pri čemu R9 je H.
A base unit (3) according to any one the claims 1-4, wherein said base unit (3) further comprises means in the form of circumferentially arranged recesses, taps or barbs for securing an inseparable connection of the base unit (3) press fit to said container (2). 
Sklop za točenje pića prema zahtjevu 7 ili 8, naznačen time, da je sredstvo za hermetičko brtvljenje sklopivog spremnika (2) prema osnovnom dijelu (5) predviđeno između vanjske stijenke (16) osnovne jedinice (3) i osnovnog dijela 5.
insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) is present in a concentration of 100 U/ml, and compound (a) is present in a concentration of 50 µg/ml, for use in the treatment of diabetes mellitus type 2, wherein the pharmaceutical composition is administrated as add-on to the treatment with metformin or/and a pharmaceutically acceptable salt thereof. 
inzulin glargin ili njegovu farmaceutski prihvatljivu sol, pri čemu je spoj (b) prisutan u koncentraciji od 100 U/ml, i spoj (a) je prisutan u koncentraciji od 50 µg/ml, naznačen time što je za upotrebu u liječenju dijabetes melitusa tipa 2, pri čemu se farmaceutski pripravak primjenjuje kao dodatak liječenju metforminom ili njegovom farmaceutski prihvatljivom soli.
In preferred embodiments, the present methods are useful for the treatment of Crohn's disease or colitis. 
(54) Naziv izuma: METODE I SASTAVI ZA LIJEČENJE UPALNE BOLESTI CRIJEVA
A pharmaceutical composition comprising the at least two different Ig-like molecules of any one of aspects 30-33, and a pharmaceutically acceptable carrier. 
Farmaceutski spoj koji sadrži najmanje dva različita antitijela u skladu s patentnim zahtjevom 13 i farmaceutski prihvatljiv nosač. HR P20191446 T1
The systemic bioavailability (F%) after oral or i.d. administration is calculated as described above in the rat model. 
Sistemska bioprihvatljivost (F%) nakon oralne ili administracije kroz dvanaesnik izračunata je kako je ranije opisano u modelu sa štakorima.
The cross-sectional view shows the juicer element 111 placed within the body of the blender container 106. 
Poprečni prikaz pokazuje sokovnik 111 postavljen unutar tijela posude mješalice 106.
Preferred salts are the aspartate (mono- or di-aspartate) or pamoate. 
Preferirane soli su aspartat (mono- ili di-aspartat) ili pamoat.
The anti-PVRIG antibody for use according ti 0,5%-1% of antiadheziv agent, i po potrebi 10%-90%, po mogućnosti 45%-75%, poželjnije 55%-65% punila. 
Anti-PVRIG antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačeno time što je anti-PVRIG antitijelo za uporabu u kombinaciji s imunostimulirajućim antitijelom, terapijom citokina ili imunomodulatornim lijekom.
wherein the container is provided with first fitting blocks of which the mutual spacing corresponds to the mutual spacing of a 40 foot container and/or second fitting blocks or so-called corner fittings of which the mutual spacing corresponds to the mutual spacing of the outermost placed fitting blocks of a 45 foot container. 
Teretni kontejner sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je kontejner dan sa prvim ugradim blokovima čiji međusoban razmak odgovara međusobnom razmaku kontejnera od 40 stopa i/ili drugim ugradim blokovima ili takozvanim kutnim elementima čiji međusobni razmak odgovara međusobnom razmaku najudaljenije postavljenih ugradih blokova kontejnera 45 stopa.
Return the trays to moulding machine. 
Vratiti posude u stroj za kalupljenje.
The compound according to claim 11 that is 
Spoj prema zahtjevu 1 koji je
The pharmaceutical composition for use according to claim 2, wherein the compound is selected from: 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je spoj odabran od sljedećih:
The process of claim 1, wherein said second solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, dimethyl acetamide, DMSO, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine metanol, etanol, propanoli i butanoli, ksilen, N-metilpirolidinon, te smjese 2 ili više njih.
is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn; 
R, predstavlja pobočni lanac aminokiselinskog ostatka Ser i Thr; R, je -CO-Aaa;
Composition for use according to claim 5, wherein said PDE5 inhibitor is selected from Avanafil, Lodenafil, Mirodenafil, Sildenafil citrate, Tadalafil, Vardenafil and Udenafil. 
Pripravak za primjenu u skladu sa zahtjevom 5, naznačen time što je inhibitor PDES5 izabran iz grupe Avanafil, Lodenafil, Mirodenafil, Sildenafil-citrat, Tadalafil, Vardenafil i Udenafil.
wherein A has the meaning as defined for a compound of formula I, and recovering the so obtained compound of formula I in free base or acid addition salt form. 
(id) te korak oporavljanja tako dobivenog spoja formule I u slobodnom bazičnom obliku ili u obliku dodatne kiselinske soli.
A pharmaceutical composition for use in a method of treating a subject having cancer comprising orally administering to the subject the pharmaceutical composition comprising a therapeutically effective amount of 5-azacytidine, wherein the composition is an immediate release composition and wherein the cancer is acute myelogenous leukemia. 
PATENTNI ZAHTJEVI Farmaceutski pripravak za upotrebu u postupku liječenja subjekta koji ima rak koji obuhvaća oralno davanje farmaceutskog pripravka subjektu koji se sastoji iz terapeutski učinkovite količine 5-azacitidina, pri čemu pripravak je pripravak s trenutnim oslobađanjem i pri čemu je rak akutna mijelogena leukemija.
The redox flow battery of claim 14, wherein the outflow path is formed at at least one surface of the opposite surfaces of the flow path frame as an outflow groove being connected to the provision hole. 
Baterija s redoks protokom u skladu s patentnim zahtjevom 11, naznačena time, da je odvodna putanja formirana na barem jednoj od suprotnih površina okvira za putanju protoka kao odvodni kanal koji je spojen na dovodni otvor.
The counter as claimed in claim 4, wherein said first engagement means is deflected radially outwardly after a predetermined degree of rotation of said first ring member, said predetermined amount of rotation of said first ring member being less than a full rotation of said first ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 5 naznačeno time da se navedeno prvo sredstvo uključenja (704) radijalno deflektira prema van nakon predodređenog stupnja Totacije navedenog prvog prstenastog elementa (201), navedeni predodređeni stupanj rotacije navedenog prvog prstenastog elementa bivajući manji od pune rotacije navedenog prvog prstenastog elementa oko navedene zajedničke osi.
Alternatively, the sealing member 8 can have other shapes such as e.g. a film applied to the capsule, an O-ring, etc. 
Alternativno, element za nepropusno zatvaranje 8 može imati druge oblike, takve kao što su na primjer, film koji se nanosi na čahuru, O-prsten i tako dalje.
Pharmaceutical composition comprising the vesicles of any of claims 1-9, and at least one pharmaceutically acceptable excipient. 
11.Farmaceutska supstancija koja obuhvaća čestice iz bilo kojeg od patentnih zahtjeva 1-6, i najmanje jedan farmaceutski prihvatljiv ekscipijent.
The compounds may also be useful to delay labour prior to elective caesarean section or transfer of the patient to a tertiary care centre, treatment of sexual dysfunction, particularly premature ejaculation, obesity, eating disorders, congestive heart failure, arterial hypertension, liver cirrhosis, nephritic or ocular hypertension, obsessive-compulsive disorder and neuropsychiatric disorders. 
Spojevi prema ovom izumu također mogu biti korisni za odgađanje trudova prije elektivnog (izbornog) carskog reza ili prebacivanja pacijenta odnosno pacijentice u centar za tercijarmu njegu, liječenje spolne disfunkcije, osobito prijevremene ejakulacije, pretilosti, poremećaja hranjenja, kongestivnog zatajenja srca, arterijske hipertenzije, ciroze jetre, bubrežne ili očne hipertenzije, opsesivno-kompulzivnog poremećaja, te neuropsihijatrijskih poremećaja.
Number of Lanes in Direction of 
Broj međunarodne objave:
A compound according to any one of Embodiments 1 to 3 or a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein R1 is selected from C1-4alkoxy, diC1-4alkylamino, —N(C2H3)2, cyclobutyl, azetidinyl, pyrrolidinyl, furanyl and oxazolyl, wherein the cyclobutyl, azetidinyl, pyrrolidinyl, furanyl or oxazolyl is unsubstituted or substituted by 1 to 2 substituents independently selected from halo, C1-4alkyl, C1-4alkoxy, diC1-4alkylamino, and hydroxycarbonyl. Embodiment 6 A compound according to any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein R3 is halo. 
Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da R' je odabran iz niza koji čine Craalkil, C,.galkoksi, amino, C,galkilamino, diC,salkilamino, -N(C2H3)2, Ca.gcikloalkil, Cy gheterocikloalkil, i Csgheteroaril, pri čemu Craalkoksi ili C,.aalkilamino od R', je nesupstituiran ili supstituiran s 1 do 2 supstituenta neovisno odabrana iz niza koji čine Craalkil i Cr4alkoksi; 1 C3.sCikloalkil, Casheterocikloalkil ili Cs.gheteroaril od R' je nesupstituiran ili supstituiran s 1 do 2 supstituenta neovisno odabrana iz niza koji čine halo, cijano, Crgalkil, haloC,ualkil, C,galkoksi, amino, Ci4alkilamino, diCiaalkilamino, i hidroksikarbonil. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da R? je halo.
is selected from the group consisting of C1-6alkyl and hydroxy substituted C1-8alkyl; 
se R6 odabire iz skupine koju sačinjavaju C1-6alkil i hidroksi skupinom supstituiran C1-8alkil;
The method of claim 2 wherein the cancer is selected from a group consisting of ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, and leukemia. 
Tak jajnika, rak gušterače, rak dojke, rak prostate i leukemija. HR P20130252 T1
In another aspect of the invention there is provided a method for applying a relatively small volume of biologically active or chemical substance to a relatively large volume of an agricultural crop comprising: 
U drugom aspektu izuma osiguran je postupak za nanošenje relativno malog volumena biološki aktivne ili kemijske supstance na relativno veliki volumen poljoprivrednih usjeva, a koji se sastoji od:
coupling the compound of formula (VII) with a compound of formula (IX): wherein: 
(e) spajanja spoja formule (VII) sa spojm formule (LX):
In one embodiment, the pharmaceutical composition is suitable for parenteral administration to a patient, suitable for administration to a patient by injection, or suitable for administration to a patient by infusion. 
. Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću infuzije.
in the percentage of at least one monosaccharide of oligosaccharide A based on total monosaccharide units of oligosaccharide A, the monosaccharide being at least 40 number% higher that the percentage of the same monosaccharide in oligosaccharide B; and/or ii) in the percentage of at least one glycosidic linkage of oligosaccharide A based on total glycosidic linkages of oligosaccharide A, the glycosidic linkage being at least 40% higher than the percentage of the same glycosidic linkage in oligosaccharide B; and/or 
u postotku najmanje jednog monosaharida od oligosaharida A temeljenog na ukupnim monosaharidnim jedinicama oligosaharida A, te je monosaharid barem 40 % veći od postotka istog monosaharida u oligosaharidu B; i/ili ii) u postotku najmanje jedne glikozidne veze oligosaharida A temeljeno na ukupnim glikozidnim vezama oligosaharida A, glikozidna veza je najmanje 40 % viša od postotka iste glikozidne veze u oligosaharidu B; i/ili iii) u stupnju polimerizacije oligosaharida A, stupanj polimerizacije oligosaharida A je barem 5 monosaharidnih jedinica niži od stupnja polimerizacije oligosaharida B.
A combination product comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis, or a prodrug thereof, for a grouped or separate administration to a subject, simultaneously or sequentially. A pharmaceutical composition comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis, or a prodrug thereof, and a pharmaceutically acceptable carrier or excipient. 
HR P20140354 T1 PATENTNI ZAHTJEVI Sastav obuhvaća agonista muskarinskih receptora odabranog iz grupe koja se sastoji od pilokarpina, cevimelina, karbakola, metakolina i betanekola, ili njihovih soli, 1 inhibitora sinteze hormona štitnjače odabranog iz grupe koja se sastoji od metimazola, karbimazola, propiltiouracila i amiodarona, ili njihovih soli, i farmaceutski prihvatljivi nosač ili ekscipijens.
The method of Paragraph 71, wherein Y is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1H-pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
. Postupak prema zahtjevu 9, naznačen time da Y je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3 [tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
or a pharmaceutically acceptable salt thereof. 
SIN ili njegova farmaceutski prihvatljiva sol, hidrat, solvat, tautomer ili stereoizomer.
In another aspect, provided herein is a pharmaceutical composition comprising the hydrobromide described above, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-5, te farmaceutski prihvatljiv nosač ili dodatak za otapanje.
The novel dihydrotetrabenazine isomers of the invention are also inhibitors of VMAT2, with Isomers C and B producing the greatest degree of inhibition. 
Izomeri cis-dihidrotetrabenazina su također inhibitoru VMAT2, pri čemu Izomeri C 1 B produciraju najveći stupanj inhibicije.
storing the solution to precipitate the crystalline form in accordance with claim 3 out of solution and thus to yield a suspension; 
(b) ostavljanje otopine da iz otopine precipitira kristalinični oblik u skladu sa zahtjevom 1 ili 2 1 da se tako dobije suspenzija;
Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of 1400 to 1800 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 2, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 2400 mg/dan u tijeku vremenskog perioda.
The pump of claim 4, carrying an impeller (105) at said first axle end (A) and at said second axle end (B). 
Crpka u skladu s patentnim zahtjevom 4, naznačena time što nosi potisnik (105) na navedenom prvom kraju osovine (A) i na navedenom drugom kraju osovine (B).
1 is a perspective view of an exemplary embodiment of the blender system; 
Slika 1 prikaz je primjera ostvarenja sustava mješalice;
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA 1 barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina 1 druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
a hybridoma capable of producing the antibody of any one of items 1 to 14 
Hibridom sposoban proizvesti protutijelo sukladno patentnom zahtjevu 1.
23 for the quantitation of DNA sequences from beef (Bos taurus); or primers comprising or consisting of the sequences of SEQ ID NOS. 
23 za kvantifikaciju DNK sekvenci govedine (Bos taurus); ili d) početnice sadržeći ili sastojeći se od sekvenci SEQ ID NOS.
a second syringe comprising buprenorphine; wherein the syringes can be directly connected to each other to form the composition of any one of claims 1-8. 
drugu injekciju koja sadrži buprenorfin; pri čemu injekcije mogu biti izravno povezane jedna s drugom da bi se oblikovao pripravak sukladno bilo kojem od zahtjeva 1-13.
The pharmaceutical formulation of claim 7, wherein the Na+ ion is present in a concentration of from 0.053 M to 0.3 M, or wherein the Na+ ion is present in a concentration of from 0.075 M to 0.3 M. 
Farmaceutska formulacija prema zahtjevu 7, naznačena time da je Na+ ion prisutan u koncentraciji od 0.053 M do 0.3 M, ili pri čemu je Na+ ion prisutan u koncentraciji od 0.075 M do 0.3 M.
Example 1.4: Directed evolution of the AOX1 promoter 
Broj objave europskog patenta:
the prevention of latent tuberculosis; 
(c) sprječavanju latentne tuberkuloze;
Information on the preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the following Patent and Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference: WO 94/27965, WO 95/03283, WO 96/33977, WO 96/33978, WO 96/33979, WO 96/33980, WO 96/33981, WO 97/30034, WO 97/38994, WO 01/66099, US 5,252,586, EP 520 722, EP 566 226, EP 602 851 and EP 635 507. 
Informacija o pripravi potrebnih polaznih materijala ili srodnih spojeva (koji mogu biti prilagođeni tako da tvore polazne materijale) može se također pronaći u slijedećim Patentnim i Prijavnim Publikacijama, iz kojih su sadržaji relevantnih poglavlja o postupcima povezani sa ovim dokumentom: WO 94/27965, WO 95/03283, WO 96/33977, WO 96/33978, WO 96/33979, WO 96/33980, WO 96/33981, WO 97/30034, WO 97/38994, WO 01/66099, US 5,252,586, EP 520 722, EP 566 226, EP 602 851 i EP 635 507.
An apparatus according to claim 1, wherein the sensor comprises at least one of a flow sensor, a thermocouple, a pressure sensor, a current sensor, a voltage sensor, and a light sensor; and wherein the first release device comprises at least one of a heating element, a vibration generator, an ultrasonic transducer, a piezoelectric transducer, and an atomizer. 
Metoda sukladno zahtjevu 10, naznačena time da senzor (240, 291, 292, 293, 294, 295) sadrži barem jedan senzor protoka, termoelement, senzor tlaka, senzor struje (293, 294), senzor napona 1 senzor svjetla (295); i pri čemu uređaj za prvo oslobađanje (118) sadrži barem jedan grijaći element, generator vibracija, ultrazvučni pretvarač, piezoelektrični pretvarač i raspršivač.